Know Cancer

or
forgot password

Quantitation of Human Brain Tumor Therapy Response by MR


Phase 0
18 Years
N/A
Open (Enrolling)
Both
Brain Tumors

Thank you

Trial Information

Quantitation of Human Brain Tumor Therapy Response by MR


The purpose of this study is to see if new MRI methods which measure information related to
water, blood flow, and chemical makeup in the brain, can give early information of how well
treatment is working in patients with brain tumors.


Inclusion Criteria:



- Patients over the age of 18 who have been diagnosed with a brain tumor of the central
nervous system and a treatment plan has been discussed.

- Must be willing/able to undergo 3 to 5 additional contrast enhanced research MRI
scans.

- You can take part in this study if you are NOT afraid of small, enclosed places.

Exclusion Criteria:

- A patient who is claustrophobic.

- Females who are pregnant or lactating.

- Patients who have electrically, magnetically or mechanically activated implants such
as heart pacemaker, magnetic surgical clips, prosthesis or or implanted neurological
stimulator.

- Any patient who has a history of allergic reactions to MR contrast agent (Omniscan,
Magnevist, MultiHance)

- Patients who require general anesthesia to complete MRI exam or patients who have had
a negative reaction to MRI sedation. (Chloral Hydrate, Pentobarbital or Versed)

- You should NOT have any metals, or implanted devices in your body, for example,
aneurysm clips, pacemakers, or artificial joints or limbs. It is extremely important
that you tell us about any and all surgeries you have had so that we might now if
there is a chance that any metal would be inside you. Also, if your job or any other
experience might have left metal fragments in your body, please let us know, as the
MRI's strong magnetic field could disturb a metal fragment in your body or interfere
with an implanted device, such as a pacemaker, causing you harm.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

To determine if new MRI methods that measure information related to the brain will give an earlier determination as to how well patients with brain tumors are responding to treatment.

Safety Issue:

No

Principal Investigator

Thomas L. Chenevert, Ph.D

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Michigan

Authority:

United States: Institutional Review Board

Study ID:

1999-0509

NCT ID:

NCT00724191

Start Date:

September 1999

Completion Date:

Related Keywords:

  • Brain Tumors
  • Brain Neoplasms

Name

Location

Univeristy of Michigan Health SystemAnn Arbor, Michigan  48109